Active — Not RecruitingPhase 4

Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

South Korea200 participantsStarted 2023-05-03

Plain-language summary

the investigators would like to compare the differences between roschvastin and atovastatin in patients who require high-dose statin/ejetimib to undergo a new generation of drug elution stent implantation for cardiovascular disease and maintain LDL cholesterol below 55 mg/dL.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 19 years of age or older
✓. Patients who underwent a new generation of drug elution stent implantation for cardiovascular disease

Exclusion criteria

✕. LDL cholesterol levels below 55 mg/dL without statin treatment
✕. Serum AST/ALT with an acute liver disease within a month or a normal upper limit that is not continuously explained
✕. Allergies or overreactions to statins
✕. Estimated Dawn of Less than 1 Year
✕. If it is determined that follow-up is not possible for more than one year
✕. Pregnancy

What they're measuring

Percentage of statins changed

Timeframe: 12 months

Rate at which LDL cholesterol remains below 55 mg/dL

Timeframe: 12 months

Trial details

NCT IDNCT05910476

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-22

View on ClinicalTrials.gov More Coronary Artery Disease trials